THE APEX TIMES
HCA Healthcare agrees to acquire The College of Health Care Professions in push to build its workforce pipeline
The Nashville hospital operator says CHCP serves more than 8,000 students a year across campuses and online, and it will retain its chancellor and CEO after closing, which is still subject to approval.
HCA Healthcare (NYSE: HCA) said it has entered into an agreement to acquire ownership of The College of Health Care Professions (CHCP), an allied healthcare education provider based in Texas. The deal was announced May 27, 2026, and HCA said closing is contingent on regulatory approval and other customary conditions. Financial terms were not disclosed in the announcement.
HCA described CHCP as one of the largest allied healthcare training providers in Texas, with the school educating more than 8,000 students annually across 10 Texas campuses and online programs. HCA added that CHCP has been operating since 1988 and has prepared more than 52,000 students for careers in healthcare, with a focus on flexible learning for adult learners.
The company said CHCP currently offers more than 20 accredited programs, including pathways in Medical Assisting, Sonography, Surgical Technology, Radiologic Technology, and Medical Coding and Billing. HCA also noted that CHCP provides continuing education nationwide for medical imaging and emerging healthcare technologies through its Medical Technology Management Institute (MTMI).
HCA said the organizations have worked together for years, including through program advisory boards, clinical sites, and career placement. In 2023, HCA collaborated with CHCP on a 12-week Medical Assistant training program aimed at upskilling staff and feeding talent into HCA’s urgent care centers across Texas. HCA said that since the program launched, more than 100 colleagues have graduated and increased their career opportunities at HCA.
Leadership is expected to remain in place at CHCP. HCA said Eric Bing will continue to lead the school as Chancellor and CEO as part of HCA Healthcare. HCA CEO Sam Hazen and Bing both framed the agreement as an extension of a long-running partnership focused on student success, academic quality, and workforce readiness.
The acquisition fits into a broader pattern of HCA expanding its education and workforce development footprint. In the announcement, HCA said it acquired majority ownership of Galen College of Nursing in 2020 and, since then, opened 20 new campuses, bringing the total to 25 campuses nationwide. HCA also pointed to Research College of Nursing in Kansas City, Missouri, and HCA Florida Mercy College of Nursing in Miami.
HCA further said the HCA Healthcare Foundation has supported education-related initiatives, including a $1.35 million grant announced in 2022 to Educate Texas to increase access to healthcare-career programs, with an additional $1 million commitment in 2025. It also cited a $1 million commitment in 2024 to a Florida education foundation consortium aimed at expanding career pathways for underserved high school students.
Still, several key deal specifics remain undisclosed. HCA did not provide purchase price, structure of consideration, expected timetable for closing, or details on how CHCP’s academic programs and operating model will change after acquisition. The company also did not elaborate on regulatory filings or which approvals are required, beyond stating the transaction is subject to regulatory approval and customary closing conditions. Investors and students are likely to focus on what happens next once the review process begins and additional documentation is filed.
Why It Matters
- The deal underscores how hospital operators are seeking direct control over parts of the workforce pipeline, particularly for non-physician clinical and technical roles.
- By adding an allied health school with both campus and online offerings, HCA may increase its ability to recruit from adult learners and other candidates already in the workforce.
- The announcement suggests greater integration between HCA care settings and training programs, including clinical site relationships and career placement efforts.
- Because HCA did not disclose the purchase price or closing timeline, the financial impact and near-term earnings effects are unclear until additional filings or updated guidance appear.
Sources
Key Facts
- HCA Healthcare agreed to acquire ownership of The College of Health Care Professions (CHCP), announced May 27, 2026.
- The transaction is subject to regulatory approval and other customary closing conditions, and terms of the agreement were not disclosed.
- CHCP serves more than 8,000 students annually across 10 Texas campuses and online programs.
- HCA said CHCP offers more than 20 accredited programs, including Medical Assisting, Sonography, Surgical Technology, Radiologic Technology, and Medical Coding and Billing.
- HCA said Eric Bing will continue to lead CHCP as Chancellor and CEO after closing.
- HCA highlighted its prior collaboration with CHCP on a 12-week Medical Assistant training program that began in 2023, with more than 100 colleagues graduating.
Healthcare Related
Eli Lilly to buy Merida Biosciences in up-to $2.875 billion cash deal, betting on an expanded autoimmune pipeline
The company agreed to acquire privately held Merida Biosciences for up to $2.875 billion in cash, including an upfront payment and milestone-based consideration.
Eli Lilly to buy Merdia Biosciences in a deal valued at up to $2.88 billion, indicating renewed focus on pipeline expansion
The acquisition, reported as worth as much as $2.88 billion, adds another chapter to Lilly’s ongoing buy-or-build approach as biotech rivals also compete for late-stage assets and platform-like capabilities.
Johnson & Johnson schedules investor call for third-quarter results on Oct. 13
The company will hold an investor conference call at 8:30 a.m. Eastern Time to discuss its third-quarter performance, according to a notice posted by Yahoo Finance.
Pfizer reaches confidential settlement in Depo-Provera litigation over alleged meningioma risk
The agreement covers multiple federal lawsuits involving its Depo-Provera contraceptive and claims of an increased risk of intracranial meningioma, according to a report.
Moderna takes August’s S&P 500 win as biotech momentum lifts MRNA shares
A Yahoo Finance review of monthly performance found Moderna leading the S&P 500 in August, rising about 158%, while Edison International finished last, down roughly 27%.
Eli Lilly CEO David Ricks frames its $25B spending push as a long-term bet beyond obesity
In a CNBC interview, Eli Lilly’s chief executive said the company’s recent deal and investment activity is aimed at extending the durability of its obesity franchise and using related technologies to target other diseases through the 2030s, while acknowledging that not every bet will succeed.
Eli Lilly investors weigh valuation after fresh FDA nod, analyst models show mixed picture
A recent market note points to an estimated 30% upside from discounted cash flow modeling, even as other valuation checks look less clear-cut after a new Food and Drug Administration approval.
Eli Lilly shares slide after report of a $2.9 billion acquisition
A market report said Eli Lilly unveiled a $2.9 billion deal tied to its Merida program, prompting investors to reassess near-term valuation and integration risks.
Healthcare’s best week since late June draws focus to a Moderna and Merck cancer trial
A rebound in healthcare equities in the week leading up to Aug. 21 traced back to trading momentum around clinical news tied to Moderna’s work and a Merck cancer study, according to a Yahoo Finance market recap.
Pfizer highlights Padcev while pushing forward PF-08634404 as part of its longer-term oncology plan
A new market report frames Pfizer’s near-term oncology momentum around Padcev, while pointing to PF-08634404 and potential label expansion efforts as catalysts the company expects to matter later.